Buzz Stocks: Biogen Inc, KLA-Tencor Corp, and Ferrari

Today's stocks to watch include Biogen Inc (BIIB), KLA-Tencor Corp (KLAC), and Ferrari (RACE)

Oct 21, 2015 at 10:18 AM
facebook twitter linkedin


U.S. benchmarks are slightly higher this morning, as traders applaud big-cap earnings and a round of M&A. Among the equities in focus are biopharmaceutical company Biogen Inc (NASDAQ:BIIB), semiconductor firm KLA-Tencor Corp (NASDAQ:KLAC), and automaker Ferrari (NYSE:RACE).

  • BIIB is 5.5% higher at $280.33 this morning, after announcing stronger-than-expected earnings and raising its full-year guidance, and unveiling a substantial workforce reduction. Biogen Inc shares have marched 41.6% lower since hitting an all-time high of $480.18 in March, but are on pace to end atop their 20-day moving average for the first time in more than a month. Still, option players were betting on a rebound, as BIIB's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is 1.81 -- in the 90th percentile of all readings taken in the past year. 

  • KLAC rocketed 24% higher to $66.71 out of the gate this morning, thanks to news that Lam Research Corporation (NASDAQ:LRCX) has agreed to purchase the firm for $10.6 billion (subscription required). This move is the latest in a series of mergers and acquisitions in the tech world. LRCX will dish out $67.02 per share for KLAC, a 24% premium over yesterday's closing price. The last time shares of KLAC traded this high was in January.

  • RACE priced its highly anticipated initial public offering (IPO) at $52 last night, at the top of the expected range. In its first session on the Big Board, Ferrari was last seen 7.1% higher at $55.70, and earlier peaked at $60.97. Meanwhile, shares of Fiat Chrysler Automobiles NV (NYSE:FCAU) -- a major RACE stakeholder -- are down 2.7% at $15.51. 
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners